CSIMarket
 
Renalytix Plc  (RNLX)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.8600 $-0.02 -2.162%
Day's High: $0.91 Week Perf: -24.56 %
Day's Low: $ 0.81 30 Day Perf: -28.93 %
Volume (M): 202 52 Wk High: $ 4.04
Volume (M$): $ 174 52 Wk Avg: $1.68
Open: $0.86 52 Wk Low: $0.24



 Market Capitalization (Millions $) 82
 Shares Outstanding (Millions) 95
 Employees -
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -101
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 1

Renalytix Plc
Renalytix Plc is a healthcare diagnostics company that specializes in developing and commercializing clinical diagnostic solutions for kidney disease. The company's main focus is on developing AI-driven predictive analytics and clinical decision support tools for kidney disease management. Renalytix aims to improve the identification and monitoring of patients at risk of kidney disease and provide personalized care plans to optimize patient outcomes. The company collaborates with leading academic institutions and healthcare providers to develop and validate its diagnostic solutions. Renalytix is headquartered in London, UK.


   Company Address: Finsgate5-7 Cranwood Street London 0
   Company Phone Number: 3139 2910   Stock Exchange / Ticker: NASDAQ RNLX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Revolutionizing Kidney Disease Management: KidneyIntelX Recognized in Final KDIGO 2024 Clinical Guideline

Published Thu, Mar 14 2024 11:01 AM UTC



Chronic Kidney Disease (CKD) affects millions of people worldwide and imposes a significant burden on healthcare systems globally. As we enter a new era of personalized medicine, risk prediction and tailored treatment plans are crucial in managing this complex and widespread condition. The inclusion of KidneyIntelX in the Final KDIGO 2024 Clinical Guideline for CKD...

Clinical Study

KidneyIntelX: Forging New Frontiers in Slowing Chronic Kidney Disease Progression and Enhancing Diabetes Control

Published Wed, Jan 10 2024 12:01 PM UTC

Chronic kidney disease (CKD) is a global public health crisis with millions of lives at stake. Patients facing this condition require innovative approaches to not only slow down disease progression but also effectively manage comorbidities such as diabetes. Recent groundbreaking studies have shed light on the remarkable potential of KidneyIntelX, a groundbreaking electronic ...






 

Renalytix Plc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com